Nissay Asset Management Corp Novo Cure LTD Transaction History

Nissay Asset Management Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$40.29 - $82.51 $7,332 - $15,016	-182 Reduced 1.8%	9,920 $411,000
Q1 2023 May 15, 2023	SELL	$56.44 - $118.81 $22,801 - $47,999	-404 Reduced 3.85%	10,102 $607,000
Q4 2022 Feb 14, 2023	SELL	$63.98 - $85.37 $15,291 - $20,403	-239 Reduced 2.22%	10,506 $770,000
Q3 2022 Nov 14, 2022	BUY	$67.99 - $89.57 $29,643 - $39,052	436 Added 4.23%	10,745 $816,000
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $8,376 - $13,305	148 Added 1.46%	10,309 $716,000
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $12,511 - $17,580	208 Added 2.09%	10,161 $842,000
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $15,091 - $24,519	201 Added 2.06%	9,953 $747,000
Q3 2021 Nov 10, 2021	BUY	$116.17 - $194.55 $53,554 - $89,687	461 Added 4.96%	9,752 $1.13 Million
Q2 2021 Aug 13, 2021	BUY	$130.4 - $225.58 $39,641 - $68,576	304 Added 3.38%	9,291 $2.06 Million
Q1 2021 May 11, 2021	SELL	$124.11 - $190.17 $19,981 - $30,617	-161 Reduced 1.76%	8,987 $1.19 Million
Q4 2020 Feb 08, 2021	BUY	$112.16 - $174.14 $1.03 Million - $1.59 Million	9,148 New	9,148 $1.58 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

Stay updated on Nissay Asset Management Corp with notifications on news.